Video

Andelyn Biosciences Capacity Update July 2025: Cell & Gene Therapy

Andelyn Biosciences has used our Curator™ adherent platform to manufacture more than 450 Phase I and II clinical batches, spanning over 17 years and covering a variety of serotypes and indications. To assess the robustness of the adherent platform and identify potential critical process parameters, historical data generated at each process step of GMP productions involving were compiled and analyzed.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Andelyn Biosciences